专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10508153B2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof 有权
公开(公告)号：US10508153B2
公开(公告)日：2019-12-17
申请号：US14743886
申请日：2015-06-18
申请人： Amgen Fremont Inc.
发明人： Richard F. Weber , Xiao Feng , Orit Foord , Larry L. Green , Jean M. Gudas , Bruce A. Keyt , Ying Liu , Palaniswami Rathanaswami , Robert Raya , Xiao Dong Yang , Jose R. F. Corvalan , Ian Foltz , Xiao-Chi Jia , Jaspal Singh Kang , Chadwick Terence King , Scott L. Klakamp , Qiaojuan Jane Su
IPC分类号： C07K16/28 , C07K16/30 , B82Y5/00 , A61K47/68 , A61K39/00
摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

2. 发明授权

US10280219B2 Antibodies to M-CSF 有权
公开(公告)号：US10280219B2
公开(公告)日：2019-05-07
申请号：US15614237
申请日：2017-06-05
申请人： Amgen Fremont Inc. , Warner-Lambert Company LLC
发明人： Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimee Kellermann , Joseph Edwin Low , James Leslie Mobley
IPC分类号： A61K39/00 , A61K39/395 , A61K38/19 , C07K16/24 , G06Q30/02 , G06Q30/06 , G06Q40/04 , G06Q50/12
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

3. 发明申请

US20160311919A1 Antibodies Directed To GPNMB And Uses Thereof 审中-公开
公开(公告)号：US20160311919A1
公开(公告)日：2016-10-27
申请号：US15053204
申请日：2016-02-25
申请人： Celldex Therapeutics, Inc. , Amgen Fremont Inc.
发明人： Feng Xiao , Xiao-Chi Jia , Meina Liang , Orit Foord , Scott Klakamp , Kam Fai Tse , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael E. Jeffers , William J. LaRochelle , Gulshan Ara , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
IPC分类号： C07K16/30 , C07K16/28 , A61K47/48
CPC分类号： C07K16/3053 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K2039/505 , A61K2039/545 , C07K16/2809 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/94
摘要： The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

4. 发明申请

US20160152713A1 ANTIBODIES TO CD40 审中-公开
公开(公告)号：US20160152713A1
公开(公告)日：2016-06-02
申请号：US14820040
申请日：2015-08-06
申请人： Amgen Fremont Inc. , Pfizer Inc.
发明人： Vahe Bedian , Ronald P. Gladue , Jose Corvalan , Xiao-Chi Jia , Xiao Feng
IPC分类号： C07K16/28 , A61N5/10 , A61N5/06 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2866 , A01K2217/05 , A61K39/3955 , A61K45/06 , A61K48/00 , A61K2039/505 , A61N5/062 , A61N5/10 , C07K16/2878 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/92
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

5. 发明申请

US20150266952A1 ANTIBODIES TO OPGL 审中-公开
标题翻译： OPGL抗体
公开(公告)号：US20150266952A1
公开(公告)日：2015-09-24
申请号：US14621072
申请日：2015-02-12
申请人： AMGEN INC. , AMGEN FREMONT INC.
发明人： William J. BOYLE , Francis H. MARTIN , Jose R. CORVALAN , C. Geoffrey DAVIS
IPC分类号： C07K16/24 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
摘要翻译：描述了与骨保护素配体（OPGL）相互作用的抗体。描述了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。描述使用OPGL抗体检测样品中OPGL的量的方法。

6. 发明授权

US08821869B2 Treatment methods using c-Met antibodies 有权
标题翻译：使用c-Met抗体的治疗方法
公开(公告)号：US08821869B2
公开(公告)日：2014-09-02
申请号：US14056716
申请日：2013-10-17
申请人： Amgen Fremont Inc. , Pfizer Inc.
发明人： Neil R Michaud , Shama Kajiji , Gary Borzillo , Vahe Bedian , Kevin G. Coleman , Larry L. Green , Xiao-Chi Jia
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K16/3076 , C07K2317/21 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合c-Met，优选人c-Met的人抗体及其抗原结合部分的抗体，其功能是抑制c-Met。本发明还涉及人抗c-Met抗体及其抗原结合部分。本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。本发明还涉及衍生自人抗c-Met抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。本发明还涉及制备人抗c-Met抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗c-Met抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的转基因动物或植物。

7. 发明申请

US20130344514A1 REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION 审中-公开
标题翻译：通过V基因操作降低人类抗体抗体的风险
公开(公告)号：US20130344514A1
公开(公告)日：2013-12-26
申请号：US13974432
申请日：2013-08-23
申请人： AMGEN FREMONT INC.
发明人： Sirid-Aimee Kellermann , Larry L. Green , Wouter Korver
IPC分类号： G01N33/68
CPC分类号： G01N33/6854 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/56 , G01N33/5088
摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
摘要翻译：本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。其他方法用于预测HAHA反应发生的可能性。还包括用于筛选抗HAHA化合物的方法。还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

8. 发明授权

US09963508B2 Human monoclonal antibodies to CTLA-4 有权
公开(公告)号：US09963508B2
公开(公告)日：2018-05-08
申请号：US14518990
申请日：2014-10-20
申请人： Amgen Fremont Inc. , Pfizer Inc.
发明人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
IPC分类号： C07K16/28 , A61K39/395 , C12N5/10 , C12P21/08 , C07H21/04 , G01N33/569 , G01N33/68 , A61K39/00
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

9. 再颁专利

USRE45847E1 Antibodies to MAdCAM 有权
标题翻译： MAdCAM的抗体
公开(公告)号：USRE45847E1
公开(公告)日：2016-01-19
申请号：US14219900
申请日：2014-03-19
申请人： Amgen Fremont Inc. , Pfizer Inc.
发明人： Nicholas Pullen , Elizabeth Molloy , Sirid-Aimee Kellermann , Larry L. Green , Mary Haak-Frendscho
IPC分类号： C12N5/00 , C07K16/28 , A61K39/00 , C07K14/705
CPC分类号： C07K16/2803 , A61K2039/505 , C07K14/70503 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/6854 , G01N2333/70503 , G01N2333/70546
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.
摘要翻译：本发明涉及特异性结合MAdCAM，优选人MAdCAM的人抗体及其抗原结合部分的抗体，其功能是抑制MAdCAM。本发明还涉及人抗MAdCAM抗体及其抗原结合部分。本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。本发明还涉及衍生自人抗MAdCAM抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。本发明还涉及制备人抗MAdCAM抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗MAdCAM抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的转基因动物或植物。

10. 发明申请

US20150044212A1 Antibodies Directed to GPNMB and Uses Thereof 审中-公开
标题翻译：针对GPNMB的抗体及其用途
公开(公告)号：US20150044212A1
公开(公告)日：2015-02-12
申请号：US14454179
申请日：2014-08-07
申请人： CELLDEX THERAPEUTICS, INC. , Amgen Fremont Inc.
发明人： Feng Xiao , Xiao-Chi Jia , Meina Liang , Orit Foord , Scott Klakamp , Kam Fai Tse , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael E. Jeffers , William J. LaRochelle , Gulshan Ara , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
IPC分类号： C07K16/30 , C07K16/28 , A61K47/48
CPC分类号： C07K16/3053 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K2039/505 , A61K2039/545 , C07K16/2809 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/94
摘要： The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
摘要翻译：本发明提供了完全与GPNMB结合的人单克隆抗体及其应用。提供了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列。本发明还提供了包含抗GPNMB抗体的免疫缀合物和使用这种免疫缀合物的方法。本发明还提供了包含抗GPNMB抗体组分和抗-CD3组分的双特异性抗体，以及使用这种双特异性抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式